Skip to content

Study · Not a test of the peptide alone · 2020

1 result

MON-285 Clinical Characteristics of Six Patients with Infundibulo-Neurohypophysitis

Nao K, Fukuda I, Nagamine T, Hada M, Kitajima Y, Ono M, Shibayama M, Kobayashi S, Tahara S, Sugihara H

Journal of the Endocrine Society8 May 2020

PMCIDPMC7212462 (opens in a new tab)PepBankPUB-91191257
Read at sourceSource pageAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

  1. 01HumanNot a test of GHRP-2 aloneCase report or seriesOther

    In one patient (#4, 37-year-old man) with suspected lymphocytic infundibulo-neurohypophysitis, a mild low GH response (not severe GHD) was seen on the GHRP‑2 test.

    In plain wordsIn one man with a pituitary inflammation disorder, a GHRP‑2 test showed a mild low growth hormone response.

    Peptide
    GHRP-2
    Outcome
    Not applicableGH response to GHRP-2 test in one patient with LINH
    Study

    n = 1

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    A mild low GH response (not severe GHD) to GHRP-2 test was seen in another patient (#4: 37 M).
    1 context sentence
    Summary · context
    Clinical characteristics of 6 patients with CDI regarded as due to LINH (M/F; 3/3, age range; 26–67 years old) were investigated.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.